VWA
CMPX icon

VSM Wealth Advisory’s Compass Therapeutics CMPX Stock Holding History

VSM Wealth Advisory’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
6,100
+3,100
+103% +$9.15K ﹤0.01% 345
2026
Q1 		$15.9K Hold
3,000
– – ﹤0.01% 316
2025
Q4 		$16.1K Buy
+3,000
New +$13.9K ﹤0.01% 286
2025
Q3 		– Sell
-3,000
Closed -$7.8K – 455
2025
Q2 		$7.8K Buy
+3,000
New +$6.19K ﹤0.01% 401

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VSM Wealth Advisory's CMPX Position: Q2 2026 in Review

VSM Wealth Advisory increased its Compass Therapeutics (CMPX) stake by 103% in Q2 2026, buying an estimated $9.15K and bringing the position to 6,100 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #345.

VSM Wealth Advisory first reported a position in CMPX in Q2 2025 and has held it in 4 quarters since. The position peaked at $16.1K in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • VSM Wealth Advisory held 6,100 shares of Compass Therapeutics worth $13.4K as of Q2 2026.
  • VSM Wealth Advisory bought 3,100 Compass Therapeutics shares in Q2 2026, an estimated $9.15K.
  • Compass Therapeutics made up ﹤0.01% of VSM Wealth Advisory's portfolio in Q2 2026, its #345 holding.
  • VSM Wealth Advisory first reported a position in Compass Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • VSM Wealth Advisory's Compass Therapeutics position peaked at $16.1K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on VSM Wealth Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.